Novartis comes under scrutiny over competition rules

The Competition Commission is investigating pharmaceuticals firm Novartis for anti-competitive practices from 2009 to 2017.

The probe concerns a range of competitive medicines treating macular diseases.

A report found Novartis aimed to prevent market access to competitors.

The commission will consider the report findings at a December 4 meeting.